We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current HTSUF market cap is 1.92B. The company's latest EPS is JPY 178.8553 and P/E is 0.14.
| Year End 29 February 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 140.99B | 114.51B | 120.19B | 128.33B | 141.71B |
| Operating Income | 22.56B | 10.81B | 9.91B | 12.03B | 12.91B |
| Net Income | 18.69B | 9.25B | 9.66B | 11.74B | 13.97B |
| Year End 29 February 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 307.4B | 299.86B | 302.86B | 313.92B | 328.78B |
| Total Liabilities | 56.65B | 46.05B | 47.97B | 55.51B | 61.7B |
| Total Equity | 250.75B | 253.81B | 254.89B | 258.41B | 267.08B |
| Year End 29 February 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 27.39B | 5.29B | 19.2B | 12.73B | 18.19B |
| Investing | -17.23B | 7.82B | -13.06B | -23.87B | -2.51B |
| Financing | -11.73B | -7.19B | -15.19B | -14.69B | -16.69B |
| Market Cap | 1.92B |
| Price to Earnings Ratio | 0.14 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.02 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 78.1M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 405 |
| 52 Week Change | -4.81% |
| 52 Week High | 36.00 |
| 52 Week Low | 23.7001 |
| Spread (Intraday) | 1.85 (7.29%) |
| Company Name | Hisamitsu Pharmaceutical Co Ltd (PK) |
| Address |
2-4-1 marunouchi chiyoda, tokyo 100-6221 |
| Website | https://www.hisamitsu.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
